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Abstract 
Aim: This work aimed to screen the antimicrobial activity of aqueous methanolic 
extracts of 13 mushroom species, collected in Bragança, against several clinical isolates 
obtained in Hospital Center of Trás-os-Montes and Alto Douro, Portugal.  
Methods and Results: Microdilution method was used to determine the Minimum 
Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC). 
MIC results showed that Russula delica and Fistulina hepatica extracts inhibited the 
growth of Gram negative (Escherichia coli, Morganella morganni and Pasteurella 
multocida) and Gram positive (Staphylococcus aureus, MRSA, Enterococcus faecalis, 
Listeria monocytogenes, Streptococcus agalactiae and Streptococcus pyogenes) 
bacteria. A bactericide effect of both extracts was observed in P. multocida, S. 
agalactiae and S. pyogenes with MBC of 20 mg/ml, 10 mg/ml and 5 mg/ml, 
respectively. Lepista nuda extract exhibited a bactericide effect upon P. multocida at 5 
mg/ml, and inhibited Proteus mirabilis at 20 mg/ml. Ramaria botrytis extract showed 
activity against E. faecalis and L. monocytogenes, being bactericide for P. multocida, S. 
agalactiae (MBCs 20 mg/ml)  and S. pyogenes (MBC 10 mg/ml). Leucopaxillus 
giganteus extract inhibited the growth of E. coli and P. mirabilis, being bactericide for 
P. multocida, S. pyogenes and S. agalactiae.  
Conclusions: Fistulina hepatica, Ramaria botrytis and Russula delica are the most 
promising species as antimicrobial agents. 
Significance and Impact of the Study: Mushrooms extracts could be an alternative as 
antimicrobials against pathogenic microorganisms resistant to conventional treatments. 
  
Keywords: Wild mushrooms; Northeast Portugal; Antimicrobial activity; Clinical 
isolates   
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Introduction 
The prevalence of infectious diseases is becoming a worldwide problem; antimicrobial 
drugs have long been used for prophylactic and therapeutic purposes, but the drug-
resistant bacterial strains have creating serious treatment problems (Klein et al. 2007; 
Steinkraus et al. 2007). Several studies carried out in Portugal with microorganisms 
such as MRSA (meticiline-resistant Staphylococcus aureus) (EARSS 2007), 
Enterococcus faecalis (Novais et al. 2004), Enterobacteriaceae (Machado et al. 2007) 
and Pseudomonas aeruginosa (Cardoso et al. 2002), revealed their high susceptibility to 
antimicrobial agents and, moreover, their increasing global virulence. In particular, the 
incidence of MRSA, in Portuguese hospitals is one of the most important in Europe 
(45%) (EARSS 2007). 
Recently, Trindade et al. (2009) reported that bacteria develop resistance to antibiotics 
through genome mutations that are crucial for their survival. Therefore, despite the 
impossibility to avoid bacteria evolution, it is important to choose the most adequate 
antibiotics to control such evolution in favor of human host.  
The huge increase of resistances associated to diseases and mortality (Shorr et al. 2006) 
is exerting a considerable pressure in health systems, mainly at hospital level. Besides 
the multi-resistance problem, the nosocomial infections (health-care associated 
infections) are associated to high mortality, as also to the increase in the internment 
period and related costs (Orsi et al. 2002; Masterton et al. 2003; Wisplinghoff et al. 
2004; Sǔljagić et al. 2005; Cosgrove 2006). Disease Control and Prevention (CDC) 
centers estimate that nosocomial infections are at least ca. 5% in all hospitalized 
patients, dealing to more than 2 millions of infections and 99.000 deaths per year 
(Wenzel and Edmond 2001; CDC 2003; CDC 2007).  
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This situation has forced the research of new antimicrobial substances effective against 
pathogenic microorganisms resistant to conventional treatments. Natural resources have 
been exploited in the last years and among them mushrooms could be an alternative as 
source of new antimicrobials.  
The Northeast of Portugal is one of the European regions with higher biodiversity in 
wild mushrooms, most of them with a great gastronomic importance. Mushrooms have 
been recognized as functional foods and as a source for the development of medicines 
and nutraceuticals (Lindequist et al. 2005; Poucheret et al. 2006). They could also be a 
source of natural antibiotics. Some mushroom extracts, including Laetiporus sulphureus 
(Turkoglu et al. 2007), Ganoderma lucidum (Gao et al. 2005) and Lentinus edodes 
(Hatvani 2001) have already demonstrated antibacterial activity. Furthermore, some 
Portuguese species studied by our research group proved to be active against Bacillus 
cereus, B. subtilis and S. aureus (Barros et al. 2007b; Barros et al. 2008). Nevertheless, 
the reports available on literature are not related with multi-resistant bacteria (MRSA, E. 
faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter 
cloacae, P. aeruginosa) that are a problem at hospital level due to the scarce options of 
active antibiotics.  
Herein, the in vitro antimicrobial activity of 13 wild mushrooms aqueous methanolic 
extracts was screened against the above mentioned multi-resistant bacteria and other 
clinical isolates from CHTMAD – Hospital Center of Trás-os-Montes and Alto Douro, 
Portugal. 
 
Materials and methods  
 
Mushroom species 
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Thirteen mushroom species were collected in different ecosystems of the Trás-os-
Montes region in the Northeast of Portugal in 2005-2010 Autumns (Table 1). The 
morphological identification of the wild macrofungi was made according to macro and 
microscopic characteristics, and following several authors (Marchand 1971; Moser 
1983; Bon 1988; Courtecuisse and Duhem 2005) and online keys 
(http://www.mycokey.com/). Representative voucher specimens were deposited at the 
herbarium of Escola Superior Agrária of Instituto Politécnico de Bragança. After 
taxonomic identification, the mushrooms were immediately lyophilized (Ly-8-FM-
ULE, Snijders, Netherlands) and kept in the dark in hermetically sealed plastic bags up 
to the point of analysis.  
 
Standards and Reagents 
Methanol was of analytical grade purity from Lab-Scan (Lisbon, Portugal). The culture 
media Muller Hinton broth (MHB), Wilkins-Chalgren Broth (WCB) and Columbia agar 
(CA) with 5% horse blood were obtained from Biomerieux (Marcy l´ Etoile, France), 
respectively. The dye p-iodonitrotetrazolium chloride (INT) was purchased from 
Sigma–Aldrich (Spruce Street; St. Louis, USA) to be used as microbial growth 
indicator. Water was treated in a Milli-Q water purification system (TGI Pure Water 
Systems, USA) before use.  
 
Extracts preparation  
Each mushroom lyophilized sample (ca. 3 g) was extracted using a methanol:water 
(80:20; 30 ml) mixture at -20 °C for 6 h. After 15 min in an ultrasonic bath, the extract 
was centrifuged at 4000 g for 10 min and filtered through Whatman nº 4 paper. The 
residue was then extracted with two additional 30 ml portions of the methanol:water 
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mixture. The combined extracts were evaporated at 40 ºC under reduced pressure to 
remove methanol (rotary evaporator Büchi R-210, Flawil, Switzerland), lyophilized, 
redissolved in water, at a concentration of 200 mg/ml, and stored at -20 ºC for further 
use. 
 
Microorganisms and culture media  
The microorganisms used were clinical isolates from patients hospitalized in various 
departments of the Hospital Center of Trás-os-Montes and Alto Douro – Chaves, 
Portugal. 
Seven Gram negative bacteria (Escherichia coli, Klebsiella pneumonia, Proteus 
mirabilis, Morganella morganii, Pseudomonas aeruginosa and Acinetobacter 
baumannii, isolated from urine and Pasteurella multocida isolated from synozial fluid) 
and nine Gram positive bacteria (Staphylococcus aureus and MRSA isolated from 
wound exudates, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus 
saprophyticus, Enterococcus faecalis and Listeria monocytogenes isolated from blood 
culture, Streptococcus agalactiae isolated from vaginal swab and Streptococcus 
pyogenes isolated from oropharyngeal swab) were used to screen the antimicrobial 
activity of the mushroom extracts. All strains were identified using the MicroScan®  
panels automated methodology - Siemens. 
Muller Hinton broth (MHB) and Wilkins-Chalgren Broth (WCB) were used for 
determination of Minimum Inhibitory Concentration (MIC, lowest concentration of the 
mushroom extract able to inhibit bacterial growth), while Columbia agar with 5% horse 
blood (CA) was used for determination of Minimum Bactericidal Concentration (MBC, 
the lowest concentration of mushroom extract at which bacterial growth was prevented, 
and the initial viability was reduced by at least 99.9 %).  
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Characterization of antibiotic susceptibility of target strains 
The characterization of antibiotic susceptibility and the identification of the target 
strains were performed using MicroScan® panels (Siemens). These panels allow the 
simultaneous determination of susceptibility to antimicrobial agents and the strain 
identification, including aerobic and facultative anaerobic Gram negative bacilli 
(MicroScan® Neg panels), and Gram positive cocci such as some fastidious aerobic 
Gram positive and Listeria monocytogenes (MicroScan® Pos panels). 
Antimicrobial susceptibility test entail miniaturizations of the                                                                                                                                                                                                              
dilution susceptibility test, where each antibiotic has been dehydrated. Each 
antimicrobial agent was previously diluted in Muller-Hinton broth with additional 
supplementation to concentrations with clinical interest. Breakpoint panels used 
concentrations equivalent to the standard breakpoints of CLSI (Clinical and Laboratory 
Standards Institute). After inoculation and rehydration with a standardized 
microorganism suspension, and further incubation at 37º C for at least 16 h, MICs 
values for each antibiotic were determined (SHD 2008). 
 
Determination of antimicrobial activity of extracts 
MIC determinations were performed by the microdilution method and the rapid p-
iodonitrotetrazolium chloride (INT) colorimetric assay following the methodology 
suggested by Kuete et al. (2011a, b) with some modifications. 
Initially, 50 µl of each mushroom extract (200 mg/ml) was diluted in 450 µl of MHB for 
all microorganisms, except for Streptococcus pyogenes, where WCB was used (final 
concentration of 20 mg/ml) and then, 200 µl of this extract solution was added in each 
well (96-well microplate).  Dilutions were carried out over the wells containing 100 µl 
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of MHB or WCB and afterwards, 10 µl of inoculum (1 ×108 cfu/ml) were added to all 
the wells. Two negative (one with MHB or WCB and the other with the mushroom 
extract) and one positive (with MHB or WCB and the inoculum) controls were 
performed. The plates were incubated at 37 °C, for 24 h, in an oven (Jouan, Berlin, 
Germany) or with humidified atmosphere containing 10% CO2 (NuAire, Plymouth, 
USA), in the case of Streptococcus.  
The MIC of the samples were detected following addition of INT (0.2 mg/ml, 40 µl) 
and incubation at 37 °C for 30 min. Viable microorganisms reduced the yellow dye to a 
pink colour. MIC was defined as the lowest mushroom extract concentration that 
prevented this change and exhibited complete inhibition of bacterial growth. For the 
determination of MBC, a portion of liquid (50 µl) from each well without changes in 
colour was plated on CA and incubated at 37 °C for 24 h. The lowest concentration that 
yielded no growth after this sub-culturing was taken as the MBC. All the assays were 
carried out in duplicate.  
 
Results  
Analysis of antibiotic susceptibility showed that some of the clinical isolates used in the 
present work are multi-resistant bacteria (Tables 2 and 3) being a problem at hospital 
level due to the scarce options of active antibiotics. A. baumannii and M. morgani are 
the Gram negative bacteria with the highest number of resistances, being evident their 
low sensibility to beta-lactamics group. E. coli shows some resistance to beta-lactamics 
antibiotics, but also to quinolones group. Furthermore, the latter group shows low 
activity against P. mirabilis (Table 2). All the Staphylococcus strains, unless S. 
saprophyticus, are beta-lactamases producers. Among them, only S. aureus presented 
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sensibility to oxacillin. The Streptococcus strains, L. monocytogenes and P. multocida, 
presented high sensibility to all the tested antibiotics (Table 3). 
Therefore, it is important to find new antimicrobials effective against these pathogenic 
microorganisms resistant to conventional treatments. Herein, wild mushrooms were 
evaluated as an alternative. Data obtained in the screening of antimicrobial activity of the 
different wild mushrooms extracts against Gram negative bacteria are shown in Table 4. It 
should be pointed out that the majority of the extracts did not present antimicrobial activity 
against the tested Gram negative bacilli, which is in agreement with the results previously 
reported by our research group concerning  E.  coli, K. pneumonia and P. aeruginosa (Barros et 
al. 2008b; Cruz et al. 2008), even when higher extract concentrations were used (Barros et al. 
2007b). Nevertheless, a recent study describes methanolic extracts obtained from Agaricus 
bisporus and Cantharellus cibarius (from black sea region of Turkey) as having high 
antibacterial activity against E. coli, assessed by disc diffusion method (Ozen et al. 2011). The 
extraction solvent or even the mushrooms origin, as well as the bacterial strain could explain the 
differences in the antimicrobial activity reported by different authors for the same species. 
 In the current study none of the tested extracts inhibited A. baumannii, K. pneumonia or P. 
aeruginosa.  However, Lepista nuda extract showed some antimicrobial activity against P. 
mirabilis and P. multocida with MIC values of 20 mg/ml and 5 mg/ml, respectively. This 
extract was completely inactive for the other tested bacilli (E. coli, K. pneumonia and P. 
aeruginosa) which is in agreement with the reported by Barros et al. (2008b) for the 
same mushrooms species. Russula delica and Fistulina hepatica extracts exhibited 
antimicrobial activity against E. coli, M. morganni and P. multocida at the highest 
tested concentration (20 mg/ml). Leucopaxillus giganteus extract also revealed activity 
against E. coli, P. mirabilis (MICs 20 mg/ml) and P. multocida (MIC 10 mg/ml) (Table 
4). 
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Among the tested Gram negative bacteria, P. multocida was the most susceptible to the 
extracts.  
The results obtained in the screening of antimicrobial activity of the different wild 
mushrooms extracts against Gram positive bacteria are shown in Table 5. Agaricus 
arvensis extract showed the lowest antimicrobial activity, being only effective against S. 
pyogenes (MIC 10 mg/ml). As observed for Gram negative bacteria, Russula delica and 
Fistulina hepatica extracts showed the highest activity also against Gram positive 
bacteria (almost all the tested bacteria, except for S. hominis and S. saprophyticus, 
respectively) with MICs between 5 mg/ml and 20 mg/ml. Other studies reported the 
high susceptibility of Gram positive bacilli to mushrooms extracts (Barros et al. 2007b; 
Barros et al. 2008a; Barros et al. 2008b). Russula delica, Fistulina hepatica and 
Ramaria botrytis extracts were the only samples showing antimicrobial activity against 
E. faecalis. Furthermore, Triholoma portentosum, Sarcodon imbricatus and Mycena 
rosea presented MICs of 20 mg/dl for S. aureus and MRSA. 
Cantharellus cibarius, Lepista nuda and Ramaria botrytis extracts did not show any 
activity against S. aureus and MRSA, at the tested concentrations (up to 20 mg/ml). 
Nevertheless, a previous report described high antimicrobial activity of those species 
against S. aureus isolated from pus (MIC 5 mg/ml) (Barros et al. 2008b). It should be 
highlighted that the authors used a different extraction solvent (methanol), a different 
antimicrobial activity assay (agar streak dilution method based on radial diffusion), they 
dissolved the extracts in DMSO and not in water as in the present study, and specially 
they used a different strain, probably with a different antibiotic resistance profile. 
A bactericidal effect of some of the studied mushrooms extracts was observed for the 
streptococci and P. multocida (Table 6). The lowest MBC values (5 mg/ml) for S. 
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pyogenes, S. agalactiae and P. multocida were achieved by Russula delica/Fistulina 
hepatica, Leucopaxillus giganteus and Lepista nuda extracts, respectively.  
 
Discussion 
The obtained results seem to be promising since some extracts were bacteriostatic for 
Gram negative bacteria and bactericidal for some Gram positive bacteria. The 
susceptible bacteria included M. morganni, MRSA, S. epidermidis and E. faecalis, 
which are multi-resistant (Table 2 and 3) and responsible for nosocomial infections. It 
is estimated that this kind of infections affects 4.1 millions of patients in EU each year, 
being responsible for a considerable increase of several diseases, mortality and related 
costs (Puupponen-Pimia et al. 2001). Although this S. agalactiae possess reduced 
resistance, there are already some reports describing S. agalactiae resistant to penicillin, 
ampicillin, erythromycin and clindamycin in different countries (Public Health; Cowan 
1999; Kuete 2010). 
Phenolic compounds might be some of the individual molecules present in the extracts 
responsible for the bioactivity, since methanol:water was used as solvent extraction. In 
fact, several authors have already related the antimicrobial activity of different natural 
matrixes with the presence and content of phenolic compounds (McGavin et al. 2001; 
D´Oliveira et al. 2003; Barros et al. 2007b).  
The best results were obtained with the most sensitive microorganisms such as P. 
multocida, L. momocytogenes and Streptococcus group. Nevertheless, it should be 
highlighted that the tested mushroom extracts revealed the same behavior against the 
methicillin susceptible S. aureus (a MSSA) and MRSA.  Therefore, more studies with S. 
aureus, but with different resistance profiles, should be performed in order to evaluate 
their behavior in the presence of a specific extract.  
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Overall, antimicrobial drugs have long been used for prophylactic and therapeutic 
purposes; however the drug-resistant bacterial strains have been creating serious 
treatment problems. This situation has forced the search of new antimicrobial 
substances effective against pathogenic microorganisms resistant to conventional 
treatments. Natural resources, such as the herein studied wild mushrooms, could be an 
alternative being included in diet taking advantage on the synergistic effects of all the 
compounds present, or giving extracts and isolated compounds that could be used as 
nutraceuticals or drugs. The studied mushrooms are edible species, and therefore, their 
ingestion should not bring toxicity. However, the toxicity of their extracts and 
individual compounds should be evaluated for further conclusions. Moreover, the 
mechanism of bacteriostatic or bactericide action of the best extracts (e.g. Fistulina 
hepatica, Ramaria botrytis and Russula delica) should be elucidated and the 
individual/combined phenolic compounds found in those extracts might be tested 
against selected bacteria in order to identify molecules responsible for the mushrooms 
bioactivity. 
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Table 1. Information on the wild mushroom samples collected.   
 
aRefers to mixed stands of Quercus sp. and Pinus sylvestris Ait. bSpecies with unknown edibility; all the 
other are edible mushrooms. 
 
Scientific name English name Ecology Habitat 
Agaricus arvensis (Shaeff.:Fr.) Horse Mushroom Saprotrophic Grassland  
Agaricus bisporus (Lange) Imbach White Mushroom Saprotrophic Grassland  
Cantharellus cibarius L.:Fries Chanterelle Mycorrhizal Pinus sp. 
Fistulina hepatica (Schaeff.:Fr) Beefsteak Fungus Parasitic Quercus pyrenaica Willd. 
Lactarius deliciosus (L.) Gray  Saffron Milk Cap Mycorrhizal Pinus sp. 
Lactarius salmonicolor (Heim y Leclair) Not known Mycorrhizal Mixed stands
a 
Lepista nuda (Bull. ex Fr.) Cooke Wood Blewit Saprotrophic Pinus sp. 
Leucopaxillus giganteus (Sowerby) Singer Giant Leucopax Saprotrophic Grassland 
Mycena rosea (Schumach.) Grambergb Rosy Bonnet Saprotrophic Mixed stands  
Ramaria botrytis (Pers.:Fr.) Ricken Cauliflower Coral Mycorrhizal Quercus pyrenaica Willd. 
Russula delica (Fr.)  Milk-white Brittlegill Mycorrhizal Mixed stands  
Sarcodon imbricatus (L.) P. Karst  Shingled Hedgehog Mycorrhizal Pinus sp. 
Tricholoma portentosum  (Fr.) Quél. Dingy Agaric Mycorrhizal Pinus sp 
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Table 2. MIC values (µg/ml) of different antibiotics against Gram negative bacteria.  
 
 
 
 E. coli K. pneumoniae P. mirabilis M. morgani P. aeruginosa A.baumannii P. multocida 
Ampicillin >16 R >16 R ≤8 S >16 R na na na 
Amoxicillin/Clavulanic Acid 16/8 I ≤8/4 S ≤8/4 S >16/8 R na na na 
Cephalothin 8 S ≤ 8 S ≤8 S >16 R na na ≤8 S 
Cefazolin ≤8 S ≤8 S ≤8 S >16 R na na ≤8 S 
Cefuroxime ≤4 S ≤4 S ≤4 S >16 R na na ≤4 S 
Cefoxitin ≤8 S ≤8 S ≤8 S ≤8 S na na ≤8 S 
Cefotaxime ≤1 S ≤1 S ≤1 S 2 S 32 I >32 R ≤1 S 
Ceftazidime ≤1 S ≤1 S ≤1 S 2 S 2 S 16 I ≤1 S 
Cefepime 16 S ≤1 S ≤1 S ≤1 S 8 S >16 R ≤1 S 
Nalidíxic Acid >16 R na >16 R ≤16 S na na na 
Norfloxacin >8 R ≤0.5 S 4 S ≤0.5 S 1 na na na 
Ciprofloxacin >2 R ≤0.5 S >2 R ≤0.5 S ≤0.5 na >2 R na 
Nitrofurantoin ≤32 S ≤32 S >64 R 64 I na na na 
Fosfomycin ≤16 S ≤16 S >64 R >64 R >64 na na na 
Gentamicin ≤2 S ≤2 S 8 I ≤2 S 4 na 4 S na 
Imipenem ≤1 S ≤1 S 2 S 4 S ≤1 na na na 
Piperacilin/Tazobactam ≤8 S ≤8 S ≤8 S ≤8 S ≤8 na na na 
Trimethoprim/Sulfasoxazole ≤2/38 S ≤2/38 S >4/76 R >4/76 R na na R na 
Tobramycin ≤2 S ≤2 S 4 S ≤2 S ≤2 na ≤2 S na 
S- Susceptible; I- Intermediate; R- Resistant (this classification was made according to the interpretative breakpoints suggested by Clinical and Laboratory Standards Institute- 
CLSI); na- not applicable. 
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Table 3.  MIC values (µg/ml) of different antibiotics against Gram positive bacteria.  
 
 
  
S. epidermidis S. aureus MRSA S. saprophyticus S. hominis-homin S. agalactiae S. pyogenes E. faecalis L. monocytogenes 
Penicillin 8 Blac 8 Blac >8 Blac 0.12 S >8 Blac ≤0.03 S 0.25 S 2 S 0.25 S 
Ampicillin 4 Blac 4 Blac >8 Blac na >8 Blac na na ≤1 S ≤1 S 
Cefoxitin Screen >4 Pos ≤4 Neg >4 Pos ≤4 Neg >4 Pos na na na na 
Oxacillin >2 R ≤0.25 S >2 R ≤0.25 S >2 R na na na na 
Clindamycin ≤0.25 S ≤0.25 S 1 I ≤0.25 S  na ≤0.25 S na na na 
Daptomycin ≤0.5 S ≤0.5 S ≤0.5 S ≤0.5 S ≤0.5 S ≤0.5 S na ≤0.5 S na 
Erythromycin >4 R ≤0.25 S ≤0.25 S >4 R >4 R ≤0.25 S na 2 I na 
Fosfomycin ≤32 S ≤32 S ≤32 S ≤32 S ≤32 S na na na na 
Gentamicin ≤1 S ≤1 S 4 S ≤1 S ≤1 S na na na na 
Ciprofloxacin ≤0.5 S ≤0.5 S >2 R ≤0.5 S 2 I na na 1 S na 
Levofloxacin ≤1 S ≤1 S >4 R ≤1 S ≤1 S ≤1 S na ≤1 S na 
Linezolid ≤1 S 2 S 2 S 4 S ≤1 S ≤1 S na ≤1 S na 
Synercid ≤0.5 S ≤0.5 S 1 S ≤0.5 S ≤0.5 S ≤0.5 S na >2 R na 
Teicoplanin ≤1 S ≤1 S 2 S 1 S 2 S na na na S na 
Tetracycline ≤1 S ≤1 S ≤1 S >8 R ≤1 S ≤1 S na ≤1 S na 
Trimethoprim/Sulfasoxazole ≤1/19 S ≤1/19 S ≤1/19 S ≤1/19 S 4/76 R na na na na 
Vancomycin ≤1 S ≤1 S 2 S ≤1 S ≤1 S ≤1 S na 2 S na 
S- Susceptible; I- Intermediate; R- Resistant (this classification was made according to the interpretative breakpoints suggested by Clinical and Laboratory Standards Institute- 
CLSI); Blac- Beta-lactamase positive; Pos- positive to Cefoxitin screening; Neg- negative to Cefoxitin screening; na- not applicable. 
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Table 4. MIC values (mg/ml) of the wild mushrooms extracts against clinical isolates of Gram negative bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Escherichia   coli 
Klebsiella  
pneumoniae 
Proteus 
mirabilis 
Morganella 
morganni 
Pseudomonas 
aeruginosa 
Acinetobacter 
baumannii 
Pasteurella 
multocida 
Agaricus arvensis > 20 > 20 > 20 > 20 > 20 > 20 20 
Agaricus bisporus > 20 > 20 > 20 > 20 > 20 > 20 20 
Cantharellus cibarius > 20 > 20 > 20 > 20 > 20 > 20 >20 
Fistulina hepatica 20 > 20 > 20 20 > 20 > 20 20 
Lactarius deliciosus >20 > 20 > 20 > 20 > 20 > 20 > 20 
Lactarius salmonicolor > 20 > 20 > 20 > 20 > 20 > 20 >20 
Lepista nuda > 20 > 20 20 > 20 > 20 > 20 5 
Leucopaxillus giganteus 20 > 20 20 > 20 > 20 > 20 10 
Mycena rosea > 20 > 20 20 > 20 > 20 > 20 >20 
Ramaria botrytis > 20 > 20 > 20 > 20 > 20 > 20 10 
Russula delica 20 > 20 > 20 20 > 20 > 20 20 
Sarcodon imbricatus >20 > 20 > 20 > 20 > 20 > 20 >20 
Tricholoma portentosum > 20 > 20 > 20 > 20 > 20 > 20 10 
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Table 5. MIC values (mg/ml) of the wild mushrooms extracts against clinical isolates of Gram positive bacteria. 
 
MRSA (Methicillin-resistant Staphylococcus aureus). 
 Staphylococcus  aureus 
MRSA 
 
Staphylococcus 
epidermidis 
Staphylococcus 
hominis 
Staphylococcus 
saprophyticus 
Enterococcus 
faecalis 
Listeria 
monocytogenes 
Streptococcus 
agalactiae 
Streptococcus 
pyogenes 
Agaricus arvensis > 20 >20 >20 >20 >20 > 20 > 20 > 20 10 
Agaricus bisporus >20 >20 >20 >20 >20 > 20 > 20 20 10 
Cantharellus cibarius > 20 >20 20 >20 > 20 > 20 20 10 20 
Fistulina hepatica 10 10 20 20 >20 20 20 5 5 
Lactarius deliciosus > 20 20 > 20 >20 >20 > 20 >20 20 20 
Lactarius salmonicolor > 20 > 20 >20 >20 >20 >20 20 >20 10 
Lepista nuda > 20 >20 20 > 20 > 20 > 20 20 10 10 
Leucopaxillus giganteus > 20 >20 >20 >20 > 20 > 20 20 5 10 
Mycena rosea 20 20 >20 >20 >20 > 20 20 >20 10 
Ramaria botrytis > 20 >20 > 20 >20 > 20 20 10 20 10 
Russula delica 10 10 10 >20 20 20 20 5 5 
Sarcodon imbricatus 20 20 > 20 >20 > 20 > 20 20 10 10 
Tricholoma portentosum 20 20 20 >20 > 20 > 20 > 20 5 10 
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Table 6. MBC values (mg/ml) of the wild mushrooms extracts against three clinical 
isolates.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(-)  MIC > 20 mg/ml 
 
 
 Pasteurella multocida 
Streptococcus 
agalactiae 
Streptococcus 
pyogenes 
Agaricus arvensis 20 - 10 
Agaricus bisporus 20 20 10 
Cantharellus cibarius - 10 >20 
Fistulina hepatica 20 10 5 
Lactarius deliciosus - 20 >20 
Lactarius salmonicolor - - 10 
Lepista nuda 5 20 10 
Leucopaxillus giganteus 10 5 10 
Mycena rosea - - 10 
Ramaria botrytis 20 20 10 
Russula delica 20 10 5 
Sarcodon imbricatus - 10 10 
Tricholoma portentosum 10 10 10 
